Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Arizona
Clinical trial register · United States · industry-sponsored

Clinical Trials in Arizona, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca114 Eli Lilly and Company96 AbbVie74 Merck Sharp & Dohme LLC62 Janssen Research & Development, LLC49
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Arizona

2238 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Hypersound Treatment for Chronic Neuropathic and Radicular Pain
NCT07831447Chronic Neuropathic Pain, Radiculopathy, Sciatica, Peripheral Neuropathic Pain
Hypersound Medical Inc
Not applicable
71
Arizona
2027-06
Not yet open
A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults
NCT07583641Autoimmune Encephalitis (AE)
argenx
Phase 2
170
Arizona, Texas
2027-04-01
Not yet open
Safety Study of XT-150 in Participants With ALS
NCT06704347Amyotrophic Lateral Sclerosis (ALS)
Xalud Therapeutics, Inc.
Phase 1
8
Arizona, Maryland, Massachusetts, Michigan
2027-03
Not yet open
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562Systemic Sclerosis
DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Arizona, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2027-02-03
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide
AbbVie
Phase 3
520
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2026-11-30
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
DrugNerandomilast
Boehringer Ingelheim
Phase 3
270
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Michigan
2026-11-09
Not yet open
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
NCT07772531Major Depressive Disorder
Bristol-Myers Squibb
Phase 2
200
Arizona, Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New York
2026-10-30
Not yet open
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
Boehringer Ingelheim
Phase 3
600
Arizona, California, Florida, Kansas, New Mexico, North Carolina
2026-10-23
Recruiting
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
NCT07775495Healthy Adult Participants
Ecotera Health LLC
Observational
15
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-10-21
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
NCT07285798Irritability Associated With Autism Spectrum Disorder
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
176
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-10-02
Recruiting
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
NCT07559175Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
DrugZenpep
Aimmune Nestlé Health Science US R&D, LLC
Phase 2
66
Arizona, Arkansas, California, Florida, Kansas, Maryland, Montana, Ohio
2026-10
Recruiting
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
NCT07473700Hypertension, Pulmonary, Lung Diseases, Interstitial
Tectonic Operating Company, Inc.
Phase 2
25
Arizona, California, Idaho, Michigan
2026-10
Recruiting
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
NCT06840496Rett Syndrome
Biomed Industries, Inc.
Phase 3
210
Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, New York
2026-09-30
Not yet open
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
NCT07725796Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
Phase 1
30
Arizona, California, Massachusetts, Nebraska, New York, Pennsylvania, South Carolina, Texas
2026-09-30
Recruiting
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT07336472Multiple Myeloma
DrugIBI3003
Fortvita Biologics (USA)Inc.
Phase 1/2
360
Arizona, California, Georgia, New York, Texas
2026-09-30
Recruiting
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07029945Geographic Atrophy
Biojiva LLC
Phase 1/2
152
Arizona, Mississippi, Nevada, Ohio, Texas, Utah, Washington
2026-09-29
Recruiting
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
NCT07700979Gastric / Gastroesophageal Junction Adenocarcinoma
DrugsFolfox·Cadonilimab·Nivolumab
Akeso
Phase 3
900
Arizona, California, Colorado, Connecticut, Massachusetts, Michigan, New York, Oregon
2026-09-24
Recruiting
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
NCT07845071Pain
Adneuris Therapeutics, Inc.
Phase 3
160
Arizona, California, Colorado, Georgia, Illinois, Maryland, New Jersey, Oklahoma
2026-09-22
Not yet open
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189Oropharyngeal Carcinoma (OPC)
DrugsCRB-701·Cetuximab·Docetaxel
Corbus Pharmaceuticals Inc.
Phase 3
260
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Maryland
2026-09-20
Not yet open
A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
NCT07723963Juvenile Myoclonic Epilepsy
DrugCannabidiol
Jazz Pharmaceuticals
Phase 2/3
260
Arizona, Connecticut, Florida, Georgia, Hawaii, Idaho, Louisiana, Michigan
2026-09-18
Recruiting
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
NCT07817251Diabetes Mellitus, Type 2
DrugCagriSema
Novo Nordisk A/S
Phase 3
210
Arizona, California, Connecticut, Florida, Hawaii, Illinois, Iowa, Kansas
2026-09-16
Recruiting
Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation
NCT07321899Severe Tricuspid Regurgitation
Medtronic Cardiovascular
Not applicable
1,186
Alabama, Arizona, California, Connecticut, Georgia, Illinois, Minnesota, New York
2026-09-11
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193Colorectal Adenocarcinoma
DrugsVVD-133214·Pembrolizumab
Vividion Therapeutics, Inc.
Phase 2
140
Arizona, Michigan, West Virginia
2026-09-11
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
NCT07284745Irritability Associated With Autism Spectrum Disorder
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-09-11
Recruiting
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia
NCT07619118Hypercholesterolaemia
DrugsRosuvastatin 1·Rosuvastatin 2
AstraZeneca
Phase 3
200
Arizona, California, Florida, Georgia, Indiana, Louisiana, Maryland, North Carolina
2026-09-10
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161Myelofibrosis, Anemia
DrugElritercept
Takeda
Phase 3
324
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Montana
2026-09-10
Recruiting
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
NCT07815665Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
DrugsEnfortumab Vedotin·Pembrolizumab
Summit Therapeutics
Phase 2/3
800
Arizona, California, District of Columbia, Florida, Minnesota, Tennessee, Washington
2026-09-10
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200Essential Thrombocythemia
DrugINCA033989
Incyte Corporation
Phase 3
426
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2026-09-08
Recruiting
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
NCT07763418Kidney Failure, Chronic
DrugGolcadomide
Bristol-Myers Squibb
Phase 1
30
Arizona, Florida
2026-09-08
Recruiting
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
NCT07609719Multiple Sclerosis
Genentech, Inc.
Phase 4
100
Arizona, Florida, Georgia, Tennessee
2026-09-02
Recruiting
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
NCT07805707Influenza, Human
GlaxoSmithKline
Phase 3
54,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-09-02
Not yet open
Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)
NCT07681778Leber Congenital Amaurosis, Leber Congenital Amaurosis (LCA)
Opus Genetics, Inc
Phase 1/2
10
Arizona, Pennsylvania, Texas
2026-09-01
Recruiting
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
NCT07624305Renal Insufficiency, Chronic
DrugsBalcinrenone/dapagliflozin·Dapagliflozin
AstraZeneca
Phase 3
2,800
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2026-09-01
Not yet open
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07816367Migraine
DrugElismetrep
Kallyope Inc.
Phase 3
1,500
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2026-09
Recruiting
Brexanolone Lifting Outcomes Of Moms
NCT07822321Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
Lipocine Inc.
Phase 3
120
Arizona, California, Colorado, Georgia, Idaho, Illinois, Louisiana, Nevada
2026-09
Recruiting
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
NCT07804615PARKINSON DISEASE (Disorder)
DrugVIM0423
Vima Therapeutics
Phase 2
80
Arizona, California, Connecticut, Florida, Georgia, Kansas, Maryland, Michigan
2026-09
Not yet open
WATER IV PCa (AS Sub-study)
NCT07650448Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
333
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2026-09
Recruiting
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
NCT07804186Uveal Melanoma
DrugsDarovasertib·Crizotinib
IDEAYA Biosciences
Phase 3
450
Arizona, California, Massachusetts, Michigan, New York, North Carolina, Ohio, Pennsylvania
2026-09
Not yet open
A Trial to Assess the Safety and Effectiveness of an Anatomic Total Shoulder System
NCT07812324Shoulder Arthroplasty, Total Shoulder Arthroplasty
Medacta USA
Not applicable
286
Arizona, Florida, Indiana, Maryland, New Hampshire, New York, Oregon, Pennsylvania
2026-09
Not yet open
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
NCT07817875Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 3
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2026-09
Recruiting
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
1,072
Arizona, California, Florida, Illinois, Michigan, Minnesota, Nebraska, New York
2026-08-31
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07743463Obesity, Overweight, Chronic Weight Management
DrugASC30 A1
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2026-08-31
Not yet open
Safety Study of Microlyte DualGuard
NCT07695688Wound Closure, Wound Care
Imbed Biosciences
Not applicable
53
Arizona, District of Columbia, Louisiana
2026-08-30
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT07743450Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
DrugASC30 A1
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2026-08-28
Recruiting
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
DrugPALI-2108
Palisade Bio
Phase 2
204
Arizona, California, Connecticut, Florida, Illinois, Louisiana, Mississippi, Missouri
2026-08-28
Recruiting
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
NCT07783802Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension
DrugClazakizumab
Eli Lilly and Company
Phase 2
120
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2026-08-27
Recruiting
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
NCT07768371IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
576
Alabama, Arizona, Arkansas, California, Georgia, Illinois, Maryland, Michigan
2026-08-27
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
NCT07729462Preventive Treatment of Migraine
DrugRimegepant
Pfizer
Phase 3
400
Arizona, California, Florida, Indiana, Massachusetts, Michigan, Missouri, Nebraska
2026-08-26
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
DrugOrforglipron
Eli Lilly and Company
Phase 3
2,001
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-08-26
Recruiting
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation
NCT07527299Atrial Fibrillation
Biosense Webster, Inc.
Not applicable
1,070
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Kentucky, New York
2026-08-26
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335Type 2 Diabetes, Cardiovascular Risk
DrugZenagamtide
Novo Nordisk A/S
Phase 3
1,778
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2026-08-24
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2026-08-24
Recruiting
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461Type 2 Diabetes
DrugSurvodutide
Boehringer Ingelheim
Phase 3
600
Alabama, Arizona, Arkansas, California, Florida, Georgia, Hawaii, Idaho
2026-08-24
Not yet open
A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144
NCT07783308Hepatic Impairment
DrugAZD4144
AstraZeneca
Phase 1
30
Arizona, Florida, Texas
2026-08-24
Recruiting
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
NCT07214376Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
Pulnovo Medical, Inc.
Not applicable
750
Arizona, Louisiana, Massachusetts, Michigan, New York, Ohio, Oklahoma, Pennsylvania
2026-08-21
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
7,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-08-21
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
DrugLenbelintide
AstraZeneca
Phase 3
1,500
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas
2026-08-20
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
DrugLenbelintide
AstraZeneca
Phase 3
2,500
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Michigan
2026-08-19
Recruiting
Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
NCT07288489Blood Loss, Surgical, Coagulation Disorder
VarmX B.V.
Phase 3
800
Arizona, California, Colorado, Delaware, Florida, Iowa, Massachusetts, Michigan
2026-08-18
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-08-14
Recruiting
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain
NCT07641504Chronic Pain, Low Back Pain
DrugLY4065967
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-08-12
Recruiting
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
NCT07619131Hypercholesterolaemia
DrugsRosuvastatin 1·Rosuvastatin 2
AstraZeneca
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-08-12
Recruiting
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
NCT07770828Dry Age-related Macular Degeneration
Ocugen
Phase 3
237
Arizona, Pennsylvania, Texas
2026-08-11
Recruiting
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
NCT07837973Overweight , Obesity, Adults
DrugALV-100
Alveus Therapeutics, Inc.
Phase 2
220
Alabama, Arizona, California, Florida, Illinois, Louisiana, Michigan, New York
2026-08-10
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411Atrial Fibrillation (AF)
DrugsCenvacibart·Apixaban
Regeneron Pharmaceuticals
Phase 3
15,364
Alabama, Arizona, California, Florida, Georgia, Indiana, Louisiana, Maryland
2026-08-10
Recruiting
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
NCT07734064Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Astellas Institute for Regenerative Medicine
Phase 1
30
Arizona, Ohio, Texas
2026-08-10
Recruiting
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
NCT07756580Glabellar Lines
DrugsAGN-151586·Botox
AbbVie
Phase 1
120
Arizona, California, Louisiana, Massachusetts, North Carolina, Tennessee, Texas
2026-08-10
Recruiting
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
NCT07752979Obesity, Overweight
DrugABBV-295
AbbVie
Phase 2
360
Alabama, Arizona, California, Florida, Idaho, Illinois, Kentucky, Missouri
2026-08-04
Recruiting
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07674654Acute Migraine
DrugElismetrep
Kallyope Inc.
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-08-03
Recruiting
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
NCT07779408Healthy Volunteers, Influenza
Sanofi
Phase 1/2
640
Arizona, California, Florida, Georgia, Illinois, Kansas, New York, South Carolina
2026-08-03
Recruiting
Cryoablation for Monomorphic Ventricular Tachycardia (VTS)
NCT07650032Ventricular Tachycardia, Sustained, Ventricular Tachycardia, Monomorphic
Adagio Medical
Not applicable
100
Arizona, California, Massachusetts, New York, Pennsylvania, South Carolina, Tennessee, Virginia
2026-08-01
Not yet open
A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.
NCT06458907Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
P+F Products + Features USA Inc.
Not applicable
780
Alabama, Arizona, California, District of Columbia, Florida, Illinois, Indiana, Kansas
2026-08
Recruiting
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
NCT07697456Crohn's Disease, Ulcerative Colitis
DrugsTrosunilimab·ABBV-701·Risankizumab
AbbVie
Phase 2
2,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-07-31
Recruiting
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
NCT07722546Graves' Disease
DrugFelzartamab
Biogen
Phase 2
60
Arizona, California, Florida, Maryland, North Carolina, Texas
2026-07-30
Recruiting
A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07732400Metabolic Dysfunction-associated Steatohepatitis (MASH)
Kriya Therapeutics, Inc.
Phase 1/2
56
Arizona, Florida
2026-07-30
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
NCT07684144Obesity, Overweight, Diabetes Mellitus, Type 2
DrugMaridebart cafraglutide
Amgen
Phase 3
950
Arizona, California, Florida, Illinois, Iowa, Kansas, Louisiana, Maryland
2026-07-29
Recruiting
Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry
NCT07538622BPH (Benign Prostatic Hyperplasia)
Zenflow, Inc.
Observational
300
Arizona, California, Florida, Idaho, New York, South Carolina, Texas
2026-07-29
Recruiting
Study of EVO756 in Adults With Migraine
NCT07616128Migraine
Evommune, Inc.
Phase 2
330
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New Jersey
2026-07-29
Recruiting
A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder
NCT07759128Generalized Anxiety Disorder
DrugUlotaront
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
576
Arizona, Florida, Nevada, New York, Texas
2026-07-28
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Louisiana
2026-07-27
Recruiting
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07601425Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
DrugATV-1601
Atavistik Bio, Inc
Phase 1/2
100
Arizona, Georgia, Indiana, Massachusetts, Minnesota, Utah
2026-07-27
Recruiting
ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain
NCT07568015Greater Trochanteric Pain Syndrome, Greater Trochanteric Pain Syndrome of Both Lower Limbs, Lateral Hip Pain
DrugTriamcinolone acetate
Brixton Biosciences, Inc.
Not applicable
100
Arizona, Georgia, Louisiana, Massachusetts, New Jersey, Oklahoma, Pennsylvania, Texas
2026-07-27
Recruiting
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
NCT07585266Gastrointestinal Stromal Neoplasms
DrugsVelzatinib·Imatinib
GlaxoSmithKline
Phase 3
800
Arizona, California, Connecticut, Maryland, Nebraska, New York, Ohio, Tennessee
2026-07-27
Recruiting
A Study to Evaluate MAR002 for Acromegaly
NCT07641179Acromegaly
DrugMAR002
Marea Therapeutics
Phase 2
72
Arizona, Ohio, Texas
2026-07-23
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer
Cogent Biosciences, Inc.
Phase 1
90
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Tennessee
2026-07-23
Recruiting
A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications
NCT07330258Parkinson's Disease
Bayer
Observational
300
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-07-21
Recruiting
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
NCT07594106Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
DrugsREGN4336·Cemiplimab
Regeneron Pharmaceuticals
Phase 1/2
265
Arizona, California, Florida, Illinois, Missouri, Texas
2026-07-20
Recruiting
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
DrugAleniglipron
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
1,100
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2026-07-17
Recruiting
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
NCT07601074Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
DrugLopinavir / Ritonavir
Daré Bioscience, Inc.
Phase 2
118
Arizona, Arkansas, Utah, Washington
2026-07-17
Recruiting
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
NCT07636785Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer
VM Discovery, Inc.
Phase 1/2
111
Arizona
2026-07-16
Recruiting
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
NCT07621809Sjögren´s Disease
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
570
Arizona, Florida, Illinois, Massachusetts, Michigan, New York, North Carolina, Oklahoma
2026-07-16
Not yet open
A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
NCT06974084Long COVID
DrugsMaraviroc·Atorvastatin
HealthBio, Inc.
Phase 2/3
252
Arizona
2026-07-15
Recruiting
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
NCT07654361Obesity, Overweight, Chronic Weight Management
DrugAleniglipron
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
3,600
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2026-07-13
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
DrugsObrixtamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 3
390
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-07-10
Recruiting
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
NCT07318610Peripheral Artery Disease (PAD)
DrugsAmrecibart·Cenvacibart·Rivaroxaban
Regeneron Pharmaceuticals
Phase 3
7,050
Alabama, Arizona, Arkansas, California, Florida, Indiana, Louisiana, North Carolina
2026-07-10
Recruiting
Comparative Self-collection for Cervical Cancer Screening Pivotal Study
NCT07758140HPV, HPV - Anogenital Human Papilloma Virus Infection
Mel Mont Medical
Not applicable
260
Arizona, California, Florida, Idaho, Montana, North Carolina, Texas, Washington
2026-07-09
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213Type 2 Diabetes Mellitus
DrugsElecoglipron·Semaglutide
AstraZeneca
Phase 3
1,200
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
900
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2026-07-06
Recruiting
Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study
NCT07324031Ventricular Arrythmia, Ventricular Fibrillation, Ventricular Tachycardia
AtaCor Medical, Inc.
Not applicable
280
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kentucky
2026-07-02
Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07365241Small Cell Lung Cancer
DrugsABBV-706·Amrubicin·Lurbinectedin·Topotecan
AbbVie
Phase 3
531
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-07-02
Recruiting
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07645924Migraine
DrugElismetrep
Kallyope Inc.
Phase 3
1,800
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-07-01
Recruiting
Caris Chromoseq Data Collection
NCT07680868Acute Myeloid Leukemia (AML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Myelodysplatic Syndromes, Myeloproliferative Neoplasm
Caris Science, Inc.
Observational
300
Arizona
2026-07
Not yet open
Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Femoral Stenting (SKYWARD Trans-Femoral IDE [Investigational Device Exemption] Study)
NCT07512128Carotid Artery Calcification, Carotid Artery Diseases
Shockwave Medical, Inc.
Not applicable
185
Arizona, Colorado, Florida, Georgia, Louisiana, Missouri, New York, North Carolina
2026-07
Not yet open
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
NCT07604285Glioblastoma
DrugMT-125
Myosin Therapeutics Inc.
Phase 1/2
36
Arizona, Florida, Minnesota
2026-07
Not yet open
AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)
NCT07640737Neuroendocrine (NE) Tumors, Advanced NET of GI Origin
Aurigene Discovery Technologies Limited
Phase 2
30
Arizona, California, Florida, Minnesota, Pennsylvania
2026-06-30
Recruiting
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
NCT07684820Chronic Obstructive Pulmonary Disease (COPD)
Expedition Therapeutics, Inc
Phase 2
600
Arizona, California, Colorado, Florida, Georgia, Indiana, Kansas, Minnesota
2026-06-30
Recruiting
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
NCT07589634Multiple Myeloma
DrugsRamantamig·Tocilizumab
Janssen Research & Development, LLC
Phase 2
230
Arizona, California, Colorado, Missouri
2026-06-30
Recruiting
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT07751042Advanced Solid Tumor
DrugKeytruda
Strand Therapeutics Inc.
Phase 1/2
220
Arizona, Massachusetts, Tennessee
2026-06-30
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
DrugElecoglipron
AstraZeneca
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-06-29
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371Moderate-to-Severe Atopic Dermatitis
DrugRezpegaldesleukin
Nektar Therapeutics
Phase 3
510
Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Kentucky
2026-06-29
Recruiting
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978Newly Diagnosed Multiple Myeloma
DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab
AstraZeneca
Phase 3
750
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2026-06-26
Recruiting
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
NCT07661056Graves Disease
DrugBHV-1300
Biohaven Therapeutics Ltd.
Phase 3
300
Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Michigan
2026-06-26
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916HIV Infections
DrugsCab Ula·Rpv La·Cabotegravir
ViiV Healthcare
Phase 3
564
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Maryland, Michigan
2026-06-25
Recruiting
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain
NCT07641517Osteoarthritis, Knee, Chronic Pain
DrugLY4065967
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-06-25
Recruiting
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
NCT07621237Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
DrugCyclobenzaprine
Tonix Pharmaceuticals, Inc.
Phase 2
360
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-06-25
Not yet open
rTMS Device for Improvement of Obsessive and Compulsive Behaviors
NCT07679750Obsessive-Compulsive Behavior
BTL Industries Ltd.
Not applicable
60
Arizona, Florida, Massachusetts
2026-06-24
Recruiting
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
NCT07705334Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
SHY Therapeutics
Phase 1
30
Arizona, Colorado, Texas
2026-06-24
Recruiting
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
NCT07357597Stomatitis
DrugDato-DXd
AstraZeneca
Phase 4
100
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho, Illinois
2026-06-24
Active, closed
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
NCT07724340Adults With Overweight/Obesity and Type 2 Diabetes
Antag Therapeutics
Phase 2
150
Arizona, California, Florida, Georgia, Utah
2026-06-19
Active, closed
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
NCT07702578AML, MDS
DrugTSC-101
TScan Therapeutics, Inc.
Phase 3
310
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2026-06-18
Recruiting
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
NCT07632001Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
Reprise Biomedical, Inc.
Not applicable
180
Arizona, Florida, Massachusetts, Missouri, New York, Ohio, Oklahoma, Texas
2026-06-15
Recruiting
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
NCT07645287HIV-1-infection
DrugsGS-3242·B/F/TAF·Lenacapavir
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Recruiting
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
NCT07673900Overweight and/or Obesity
DrugsWegovy·Semaglutide
Terrestrial Bio, Inc.
Phase 1
62
Arizona
2026-06-15
Recruiting
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT07104032Relapsed/Refractory Primary Central Nervous System Lymphoma
DrugsTirabrutinib·Temozolomide·Rituximab
Ono Pharmaceutical Co., Ltd.
Phase 3
132
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, Massachusetts, Minnesota
2026-06-12
Active, closed
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT07553299Obesity, Overweight, Weight Maintenance
DrugEcnoglutide
Verdiva Bio Dev Limited
Phase 2
120
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Illinois, Kansas
2026-06-12
Active, closed
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
NCT07656727Obesity and Cardiovascular Risk
DrugBGE-102
BioAge Labs, Inc.
Phase 2
160
Arizona, Arkansas, Florida, Kentucky, Maryland, Missouri, Nevada, New York
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-06-11
Recruiting
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
NCT07220915Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
DrugPanzyga
Octapharma
Phase 3
360
Arizona, Texas
2026-06-10
Recruiting
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
NCT07682896Graves' Disease
Yarrow Bioscience, Inc.
Phase 2
232
Arizona, California, Florida, Georgia, Kentucky, Michigan, Nebraska, New York
2026-06-10
Recruiting
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
NCT06622057Biliary Tract Cancer (BTC)
DrugD07001-Softgel
InnoPharmax Inc.
Phase 3
240
Arizona, Florida, Ohio
2026-06-09
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Immuneering Corporation
Phase 3
510
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2026-06-05
Recruiting
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NCT07359820FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Elevar Therapeutics
Phase 2
30
Arizona, Florida, Illinois, Massachusetts, Minnesota, New York, Texas
2026-06-04
Recruiting
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy
NCT07675135EDS, Cataplexy, Fatigue, Narcolepsy
DrugPitolisant
Harmony Biosciences Management, Inc.
Phase 3
258
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-06-04
Recruiting
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
NCT07645820Atopic Dermatitis
Castle Biosciences Incorporated
Observational
450
Arizona, Maryland, Michigan, Missouri, Nevada, New Hampshire, Texas, Virginia
2026-06-04
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Arizona, California, Colorado, Florida, Minnesota
2026-06-03
Recruiting
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
NCT07489885Psoriasis
DrugD-2570
InventisBio Co., Ltd
Phase 2
75
Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kentucky
2026-06-03
Recruiting
Study of ALK-001 on the Progression of Stargardt Disease
NCT07419334Stargardt Disease
DrugALK-001
Alkeus Pharmaceuticals, Inc.
Phase 3
230
Arizona, Colorado, Florida, Massachusetts, Michigan, Ohio, Pennsylvania, Texas
2026-06-03
Recruiting
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
NCT07630649Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Adverum Biotechnologies, Inc.
Phase 2
15
Arizona, California, Florida, Hawaii, Illinois, New Jersey, South Carolina, Texas
2026-06-02
Recruiting
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
NCT07592273Diabetic Retinopathy
DrugSurabgene Lomparvovec
AbbVie
Phase 2/3
576
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maine
2026-06-01
Not yet open
A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
NCT06287918Solid Tumors With FGFR2 Alterations, Adult
Drug3HP-2827
3H (Suzhou) Pharmaceuticals Co., Ltd.
Phase 1
130
Arizona, Texas
2026-06
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-31
Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
NCT07480356Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
DrugTARA-002
Protara Therapeutics
Phase 3
284
Arizona, Arkansas, California, Georgia, Missouri, South Carolina, Texas
2026-05-29
Recruiting
A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT07419841Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
Compass Therapeutics
Phase 1
70
Arizona, Florida, Minnesota, Nebraska, New York, Pennsylvania, South Carolina, Tennessee
2026-05-28
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-28
Recruiting
Post-Market Clinical Study Using TRAQ™ for Minimally Invasive Posterior Sacroiliac Joint Fusion
NCT07547215Sacroiliac Joint Dysfunction, Sacroiliac Joint Pain
PainTEQ, LLC
Observational
100
Arizona
2026-05-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521Ocular Myasthenia Gravis
DrugRozanolixizumab
UCB Biopharma SRL
Phase 3
120
Arizona, Illinois, New York, Ohio, Wisconsin
2026-05-27
Recruiting
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
NCT07559474Hepatic Insufficiency, Liver Diseases
DrugINCB123667
Incyte Corporation
Phase 1
16
Arizona, Florida, Texas
2026-05-27
Recruiting
Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma
NCT07665892Safety in Asthma Patients
Aspeya, Inc.
Phase 1
40
Arizona, California, Texas
2026-05-26
Recruiting
Clareon TruPlus Study
NCT07502456Aphakia, Astigmatism
Alcon Research
Not applicable
122
Arizona, Ohio, South Carolina, Texas, Utah
2026-05-26
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab
AbbVie
Phase 3
990
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-05-22
Recruiting
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT07621718Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsZoldonrasib·Leucovorin·Irinotecan·Adrucil
Revolution Medicines, Inc.
Phase 3
670
Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2026-05-22
Recruiting
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
NCT07527910Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
DrugsAln-Pnp·Tirzepatide
Regeneron Pharmaceuticals
Phase 2
204
Arizona, California, Florida, Louisiana, Texas
2026-05-22
Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582Alzheimer Disease, Dementia, Plaque, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 3
550
Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa
2026-05-22
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
NCT07492641HR+/HER2- Breast Cancer
DrugsBGB-43395·Abemaciclib·Ribociclib·Palbociclib
BeOne Medicines
Phase 3
1,056
Alabama, Alaska, Arizona, Arkansas, California, Florida, Georgia, Hawaii
2026-05-22
Recruiting
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
NCT07479797Relapsed or Refractory Large B-cell Lymphoma
DrugsKITE-753·Axicabtagene Ciloleucel·Fludarabine·Cyclophosphamide
Kite, A Gilead Company
Phase 3
550
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Missouri
2026-05-22
Recruiting
A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants
NCT07610005Healthy
Immunome, Inc.
Phase 1
20
Arizona
2026-05-21
Recruiting
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
NCT07428616Meningioma
DrugZanzalintinib
Exelixis
Phase 2
100
Alabama, Arizona, California, Florida, Louisiana, Massachusetts, Missouri, New York
2026-05-21
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282High Risk Smoldering Multiple Myeloma (HR-SMM)
DrugsLinvoseltamab·Darzalex·Daratumumab
Regeneron Pharmaceuticals
Phase 3
270
Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio
2026-05-21
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT07422480Myelodysplastic Syndrome, Anemia
DrugsElritercept·Epoetin Alfa
Takeda
Phase 3
300
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana
2026-05-21
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414Obesity, Type 2 Diabetes
DrugsCagriSema·Semaglutide
Novo Nordisk A/S
Phase 3
2,500
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-21
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Massachusetts
2026-05-20
Recruiting
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
NCT07527650Type 2 Diabetes Mellitus, T2DM
DrugHM15275
Hanmi Pharmaceutical Company Limited
Phase 2
180
Arizona, Florida, Georgia, Indiana, Missouri, Nebraska, Nevada, North Carolina
2026-05-18
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450Acute Ischemic Stroke
DrugTAK-755
Takeda
Phase 2
222
Arizona, California, Massachusetts, New York, Pennsylvania, Tennessee, Texas
2026-05-17
Recruiting
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
NCT07589608Overweight, Obesity
DrugsMacupatide·Eloralintide
Eli Lilly and Company
Phase 2
400
Arizona, California, Connecticut, Florida, Idaho, Illinois, Kansas, Kentucky
2026-05-15
Recruiting
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
NCT07610473Major Depressive Disorder (MDD)
DrugDT-101
Draig Therapeutics Ltd
Phase 2
118
Arizona, Arkansas, California, Florida, Georgia, Illinois, Massachusetts, New York
2026-05-14
Recruiting
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
NCT07387549Primary Sclerosing Cholangitis
DrugElafibranor
Ipsen
Phase 3
350
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-05-14
Recruiting
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
NCT07553429Diabetic Macular Edema
Boehringer Ingelheim
Phase 1/2
49
Arizona, California, Connecticut, Florida, New York, North Carolina, North Dakota, Ohio
2026-05-14
Recruiting
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT07287098Breast Neoplasms
DrugsImlunestrant·Goserelin·Tamoxifen
Eli Lilly and Company
Phase 2
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky
2026-05-13
Recruiting
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
NCT07503886Dry Eye Disease (DED)
DrugDFL24498
Dompé Farmaceutici S.p.A
Phase 2
417
Arizona, California, Florida, Georgia, Indiana, Minnesota, Missouri, North Carolina
2026-05-12
Recruiting
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
NCT07286214Polymyalgia Rheumatica
DrugSarilumab
Sanofi
Phase 4
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Missouri
2026-05-12
Recruiting
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399Obesity or Overweight
DrugMaridebart cafraglutide
Amgen
Phase 3
300
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Louisiana
2026-05-11
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
5,610
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2026-05-11
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
5,700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-11
Active, closed
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
DrugsPF-08653945·Berobenatide
Pfizer
Phase 2
940
Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-11
Recruiting
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
NCT07535034Gout
DrugDotinurad
Crystalys Therapeutics
Phase 2
90
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-05-08
Recruiting
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NCT07214532Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Natera, Inc.
Not applicable
725
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana
2026-05-08
Recruiting
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
NCT07610837Liver Fibrosis, Hepatic Cirrhosis
AstraZeneca
Phase 2
104
Arizona, Florida, Missouri, Nevada, North Carolina, Ohio, Oklahoma, Tennessee
2026-05-07
Recruiting
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
NCT07606066Type 2 Diabetes
AstraZeneca
Observational
2,150
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Maryland
2026-05-06
Recruiting
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031Solid Tumors
DrugsAdagrasib·Fluorouracil·Leucovorin·Cetuximab
Mirati Therapeutics Inc.
Phase 2
170
Arizona, California, Delaware, Florida, Kansas, Massachusetts, Minnesota, Nebraska
2026-05-06
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Arizona, California, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota
2026-05-06
Recruiting
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
NCT07555483Alpha 1 Antitrypsin Deficiency
Grifols Therapeutics LLC
Phase 3
40
Alabama, Arizona, California, Florida, Minnesota, Ohio, South Carolina, Texas
2026-05-05
Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Arizona, Florida, Georgia, Illinois, New York, North Dakota, Ohio, Pennsylvania
2026-05-05
Recruiting
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110Metastatic Castration-resistant Prostate Cancer
DrugsXofigo·FPI-2265·Cabazitaxel·Zytiga
AstraZeneca
Phase 3
670
Alabama, Arizona, California, Colorado, Florida, Illinois, Louisiana, Michigan
2026-05-04
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073Colitis, Ulcerative, Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
NCT07335588Lichen Sclerosus
DrugDelgocitinib
LEO Pharma
Phase 3
652
Alabama, Arizona, California, District of Columbia, Florida, Minnesota, New York, Ohio
2026-05-01
Recruiting
Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
NCT07610395Rhinovirus Infection
Altesa Biosciences, Inc.
Phase 2
180
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-05-01
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2026-05
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
NCT07567846Advanced Prostate Cancer, Metastatic Prostate Cancer
Genentech, Inc.
Phase 1/2
260
Arizona, Tennessee
2026-04-29
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772Irritable Bowel Syndrome, Constipation
DrugBrenipatide
Eli Lilly and Company
Phase 2
342
Arizona, California, Florida, Illinois, Indiana, Kentucky, New York, Ohio
2026-04-29
Recruiting
52-week Open Label Safety-Tolerability Study
NCT07369154Schizophrenia
DrugLB-102
LB Pharmaceuticals Inc.
Phase 3
900
Arizona, Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri
2026-04-23
Recruiting
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332Pulmonary Arterial Hypertension
Inhibikase Therapeutics
Phase 3
486
Arizona, California, Colorado, Kansas, Kentucky, Massachusetts, Missouri, New York
2026-04-23
Recruiting
Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants
NCT07250633Severe Hepatic Impairment, Normal Hepatic Function
DrugVorasidenib
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 1
20
Arizona, Florida, Texas
2026-04-23
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Arizona, California, Colorado, Florida, Illinois, Indiana, New York, Oregon
2026-04-23
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
NCT07502443Narcolepsy Type 2
DrugAlixorexton
Alkermes, Inc.
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-22
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
NCT07425522Diabetic Macular Edema
DrugFaricimab
Genentech, Inc.
Phase 1
93
Arizona, California, Florida, Maryland, Pennsylvania, Tennessee, Texas, Virginia
2026-04-21
Recruiting
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT07531095Small Cell Lung Cancer
DrugsZL-1310·Tarlatamab·Durvalumab
Amgen
Phase 1
160
Arizona, Florida, Illinois, Minnesota, New York, Tennessee, Virginia
2026-04-21
Recruiting
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
NCT07489651Generalized Anxiety Disorder
DrugRE104
Reunion Neuroscience Inc
Phase 2
160
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Michigan
2026-04-20
Recruiting
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
NCT07486960Psoriatic Arthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
140
Arizona, California, Florida, Idaho, Maryland, Missouri, Nebraska, New York
2026-04-20
Recruiting
Post Market Evaluation of Real World Outcomes and Durability to Support Implantable Inceptiv™ Spinal Cord Stimulation Therapy
NCT07507422Chronic Pain, Intractable Pain
Medtronic
Observational
970
Arizona, California, Missouri, Texas
2026-04-17
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, New York
2026-04-17
Recruiting
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
NCT07546500Ovarian Cancer
DrugAzenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Arizona, California, New Jersey, Ohio, Oregon, Pennsylvania, South Dakota
2026-04-17
Recruiting
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT07287670Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics
Phase 2
85
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Minnesota
2026-04-16
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT07496567Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Kansas
2026-04-15
Recruiting
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
NCT07282847Pompe Disease (Late-onset), Pompe Disease Late-Onset, LOPD
AskBio Inc
Phase 1/2
12
Arizona, California, New York, North Carolina, Pennsylvania, Texas, Virginia
2026-04-15
Recruiting
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
NCT07210515Complex Regional Pain Syndrome Type I
Ambros Therapeutics, Inc.
Phase 3
270
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2026-04-14
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Arizona, California, Florida, Georgia, Indiana, Massachusetts, Michigan, New Hampshire
2026-04-14
Recruiting
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07481630Obesity, Knee Osteoarthritis (OA)
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
400
Arizona, California, Connecticut, Florida, Georgia, Idaho, Massachusetts, Nevada
2026-04-13
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
NCT07430306Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
245
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-04-13
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
DrugINCB161734
Incyte Corporation
Phase 3
588
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia
2026-04-09
Recruiting
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT07519395Irritable Bowel Syndrome
DrugCamlipixant
GlaxoSmithKline
Phase 2
420
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-04-08
Recruiting
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
NCT07535112Advanced/Metastatic Colorectal Adenocarcinoma
DrugCetuximab
Bayer
Phase 1
130
Arizona, California, Colorado, New York, Texas
2026-04-07
Recruiting
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
NCT07424404Schizophrenia, Autism-Related Irritability
DrugsKarX-EC·KarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-04-07
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
NCT07455383Narcolepsy Type 1
DrugAlixorexton
Alkermes, Inc.
Phase 3
150
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-06
Active, closed
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
NCT07497880Obesity, Overweight
Kailera
Phase 2
306
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana
2026-04-06
Recruiting
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
NCT07288112Refractory Melanoma
DrugDOC1021
Diakonos Oncology Corporation
Phase 1/2
35
Alabama, Arizona, California, Massachusetts, New Jersey, North Carolina, Texas
2026-04-06
Recruiting
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
NCT07456696Post Traumatic Stress Disorder
DrugMethylone
Transcend Therapeutics
Phase 3
300
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Louisiana
2026-04-02
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Florida, Maryland, Michigan, Missouri, Nevada
2026-04-02
Recruiting
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
NCT07556159Asthma
Sanofi
Observational
2,500
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Montana
2026-04-01
Recruiting
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
NCT07185880Glioblastoma (GBM)
DrugMT-125
Myosin Therapeutics Inc.
Phase 1/2
36
Arizona, Florida, Minnesota
2026-04-01
Recruiting
A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study)
NCT07355270Type-2 Diabetes Mellitus
Aqua Medical, Inc.
Not applicable
20
Arizona, California, North Carolina
2026-04-01
Recruiting
Establishing Normative Urodynamics Parameters for the Glean Urodynamics System in Healthy Adults
NCT07485205Lower Urinary Tract Symptoms (LUTS)
Bright Uro
Not applicable
72
Arizona, California
2026-03-31
Recruiting
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT07454642Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
Avacta Life Sciences Ltd
Phase 1
174
Arizona, Florida, Illinois, Michigan, New York, Texas, Virginia
2026-03-31
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, Michigan
2026-03-27
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2026-03-26
Active, closed
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
NCT07446998Obesity & Overweight, Mobility Disability, HOMA-IR
DrugSemaglutide (Wegovy)
Veru Inc.
Phase 2
239
Arizona, Florida, Louisiana, Maryland, Mississippi, New York, North Carolina, Texas
2026-03-26
Recruiting
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
NCT06947941Alzheimer Disease, Psychosis
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
325
Arizona, California, Florida, Ohio
2026-03-25
Recruiting
Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis
DrugKPL-387
Kiniksa Pharmaceuticals International, plc
Phase 2
120
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Minnesota, Missouri
2026-03-25
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019Secondary Progressive Multiple Sclerosis
DrugOrelabrutinib
Zenas BioPharma (USA), LLC
Phase 3
990
Arizona, California, Florida, Indiana, Kansas, Massachusetts, Michigan, Missouri
2026-03-23
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 3
1,600
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Louisiana
2026-03-23
Recruiting
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
NCT07524348Advanced Solid Tumors
Samsung Bioepis Co., Ltd.
Phase 1
149
Arizona, Virginia
2026-03-23
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463Multiple Sclerosis (MS) Primary Progressive
DrugOrelabrutinib
Zenas BioPharma (USA), LLC
Phase 3
705
Arizona, California, Florida, Kansas, Missouri, New Jersey, North Carolina, Ohio
2026-03-23
Recruiting
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
NCT07546760Hepatic Impairment
DrugsAZD9550·Lenbelintide
AstraZeneca
Phase 1
28
Arizona, California, Florida, Texas
2026-03-20
Recruiting
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
NCT07532603Lichen Planopilaris
DrugBrepocitinib
Priovant Therapeutics, Inc.
Phase 2/3
342
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2026-03-19
Recruiting
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
NCT07448155Healthy Participants
DrugINCA033989
Incyte Corporation
Phase 1
126
Arizona
2026-03-19
Recruiting
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07474792Plaque Psoriasis
DrugORKA-002
Oruka Therapeutics, Inc.
Phase 2
160
Alabama, Arizona, California, Connecticut, Florida, Illinois, Massachusetts, Michigan
2026-03-19
Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
DrugsMarlotamig·Ubamatamab·Sarilumab
Regeneron Pharmaceuticals
Phase 2
300
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Indiana
2026-03-18
Recruiting
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT07387367Adenovirus Infections
SymBio Pharmaceuticals
Phase 3
180
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2026-03-17
Recruiting
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
NCT07482176Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
DrugAflibercept
Adverum Biotechnologies, Inc.
Phase 3
534
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-03-16
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Alabama, Arizona, California, Connecticut, Georgia, Hawaii, Illinois, Kentucky
2026-03-16
Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
NCT07143019Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm
phenox Inc.
Not applicable
214
Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Massachusetts
2026-03-16
Recruiting
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
NCT07500090Idiopathic Hypersomnia
DrugPitolisant
Harmony Biosciences Management, Inc.
Phase 3
248
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Michigan
2026-03-16
Recruiting
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
NCT07285070Non-infectious Anterior Uveitis
Novaliq GmbH
Phase 2
20
Arizona, Florida, Massachusetts, New Jersey, Texas, Virginia
2026-03-16
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
DrugsPumitamig·Folfox·Nivolumab
Bristol-Myers Squibb
Phase 2/3
690
Arizona, California, Florida, Georgia, Illinois, Iowa, Minnesota, Missouri
2026-03-13
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-03-12
Recruiting
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
NCT07339111Knee Cartilage Defects
Medipost, Inc.
Phase 3
300
Alabama, Arizona, California, Colorado, Illinois, Kentucky, Louisiana, Michigan
2026-03-11
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,182
Arizona, California, Colorado, Florida, Maryland, Ohio, Tennessee, Texas
2026-03-11
Recruiting
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
NCT07235917Functional Hypothalamic Amenorrhea, FHA
DrugMibavademab
Regeneron Pharmaceuticals
Phase 2
34
Arizona, California, Connecticut, Florida, Oregon, Pennsylvania, Texas, Virginia
2026-03-11
Recruiting
Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue
NCT07498218Diabetic Foot Ulcer (DFU), Granulation of Chronic Diabetic Wounds
Ayu, Inc.
Phase 1
24
Arizona
2026-03-11
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Arizona, California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Nevada
2026-03-09
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
DrugsIdelalisib·Pirtobrutinib
Eli Lilly and Company
Phase 4
150
Alabama, Arizona, Florida, Minnesota, New York, Ohio, Texas
2026-03-09
Recruiting
Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)
NCT07277582Long QT Syndrome (LQTS) 2
Thryv Therapeutics, Inc.
Phase 2/3
84
Arizona, California, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2026-03-07
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
DrugsINCA33890·Folfox·Bevacizumab
Incyte Corporation
Phase 3
700
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-05
Recruiting
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07450859Pancreatic Ductal Adenocarcinoma (PDAC)
DrugNuzefatide pevedotin
BicycleTx Limited
Phase 2
39
Arizona, Florida, Minnesota, Missouri, New York, Pennsylvania
2026-03-05
Active, closed
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252Overweight or Obesity and Elevated Liver Fat
DrugMaridebart cafraglutide
Amgen
Phase 2
180
Arizona, California, Florida, Louisiana, Maryland, Missouri, Nevada, Texas
2026-03-05
Active, closed
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
NCT07458269Obesity
DrugRibupatide
Kailera
Phase 2
264
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-03-04
Recruiting
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
DrugIDE397
IDEAYA Biosciences
Phase 1
260
Arizona, California, District of Columbia, Florida, Illinois, Minnesota, Nebraska, New Jersey
2026-03-04
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Alabama, Arizona, California, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2026-03-03
Recruiting
GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study
NCT07166133Aortic Arch Dissection, Aortic Arch Aneurysm
W.L.Gore & Associates
Not applicable
125
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, North Carolina, Pennsylvania
2026-03-02
Active, closed
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07427797Moderate to Severe Glabellar Lines
DrugCorabotase
Ipsen
Phase 3
309
Alabama, Arizona, California, Florida, Maryland, South Carolina, Texas, Virginia
2026-02-27
Recruiting
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
NCT07325526Liver Cirrhosis
Boehringer Ingelheim
Phase 2
30
Arizona, California, Colorado, Florida, Georgia, Iowa, Kansas, Maryland
2026-02-27
Recruiting
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865Primary Sjogren's Disease
DrugTelitacicept
Vor Biopharma
Phase 3
250
Arizona, California, Colorado, Florida, Idaho, Illinois, Louisiana, Maryland
2026-02-26
Recruiting
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
NCT07437105Cystic Fibrosis
DrugsD-Iva·Deutivacaftor·Tezacaftor
Vertex Pharmaceuticals Incorporated
Phase 1
160
Arizona
2026-02-25
Recruiting
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
NCT07484217Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
DrugSolriamfetol
Axsome Therapeutics, Inc.
Phase 3
508
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada
2026-02-23
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
DrugsAZD0120·Darzalex·Velcade·Carfilzomib
AstraZeneca
Phase 3
508
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-02-23
Recruiting
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
NCT07449702Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
240
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Maryland, Massachusetts
2026-02-23
Recruiting
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06842498Metastatic Castration-Resistant Prostate Cancer
Kyntra Bio
Phase 2
75
Arizona, California, Connecticut, Florida, Georgia, Louisiana, New Mexico, North Carolina
2026-02-22
Recruiting
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
NCT07425574Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Astellas Pharma Global Development, Inc.
Observational
90
Arizona, California, Florida, Illinois, Michigan, Mississippi, North Carolina, Ohio
2026-02-20
Recruiting
Study of DISC-0974-201 in Participants With IBD and Anemia
NCT07368972Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia
DrugDISC-0974
Disc Medicine, Inc
Phase 2
21
Alabama, Arizona, California, Florida, Missouri, Ohio, Rhode Island, Texas
2026-02-20
Active, closed
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07368959Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Aurion Biotech
Phase 3
130
Arizona, Arkansas, Colorado, Georgia, Missouri, North Carolina, Pennsylvania, South Carolina
2026-02-19
Recruiting
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
NCT07409103Active Rheumatoid Arthritis
Elevara Medicines Limited
Phase 2
180
Arizona, California, Colorado, Florida, Louisiana, Michigan, North Carolina, Pennsylvania
2026-02-18
Recruiting
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
DrugsCemsidomide·Dexamethasone
C4 Therapeutics, Inc.
Phase 2
100
Alabama, Arizona, California, Florida, Georgia, Indiana, Iowa, Michigan
2026-02-18
Recruiting
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
NCT07362017Moderate-to-severe Chronic Plaque Psoriasis
DrugPonesimod
Vanda Pharmaceuticals
Phase 3
300
Arizona, California, Florida, Indiana, New Hampshire, New York, North Carolina, Texas
2026-02-17
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsSetidegrasib·Levofolinate·Liposomal Irinotecan·Fluorouracil
Astellas Pharma Global Development, Inc.
Phase 3
614
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Indiana, Kentucky
2026-02-17
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-02-16
Recruiting
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
NCT07285018Diabetic Peripheral Neuropathic Pain
DrugLY4065967
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-02-16
Recruiting
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07491458MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugHU6
Rivus Pharmaceuticals, Inc.
Phase 2
180
Arizona, Arkansas, California, Florida, Illinois, Louisiana, Michigan, Minnesota
2026-02-13
Recruiting
A Study of Brenipatide in Participants With Opioid Use Disorder
NCT07420283Opioid Use Disorder
DrugsBuprenorphine·Brenipatide
Eli Lilly and Company
Phase 2
465
Arizona, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maryland
2026-02-13
Recruiting
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
NCT07432295Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
DrugsGivastomig·5Fluorouracil·Leucovorin·Adrucil
I-Mab Biopharma US Limited
Phase 2
180
Arizona, California, Massachusetts
2026-02-11
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694Moderate to Severe Chronic Obstructive Pulmonary Disease
Pfizer
Phase 2/3
1,156
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2026-02-11
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-10
Recruiting
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702Sepsis, Acute Kidney Injury
DrugAZD4144
AstraZeneca
Phase 2
124
Arizona, California, Kansas, Maryland, Massachusetts, Michigan, New York, North Carolina
2026-02-10
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm
DrugsCasdatifan·PF-08634404·Axitinib·Yervoy
Pfizer
Phase 1/2
224
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2026-02-10
Active, closed
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract
NCT07395986Age Related Cataracts
Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
Phase 2
8
Arizona, California, Colorado, Florida, Georgia, Illinois, North Carolina, North Dakota
2026-02-10
Active, closed
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
NCT07425392Pneumococcal Vaccines
Drugs31-valent pneumococcal conjugate vaccine·Prevnar 20
Vaxcyte, Inc.
Phase 3
752
Arizona, Connecticut, Florida, Georgia, Indiana, Kansas, Louisiana, Maryland
2026-02-09
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Active, closed
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2026-02-09
Active, closed
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441Multiple Myeloma
DrugRamantamig
Janssen Research & Development, LLC
Phase 2
168
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2026-02-08
Recruiting
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
NCT07280013Multiple Myeloma (MM)
DrugsCemsidomide·Elranatamab
C4 Therapeutics, Inc.
Phase 1
60
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-02-06
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
1,980
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Iowa
2026-02-06
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia
NCT07304089Dystonia
DrugVIM0423
Vima Therapeutics
Phase 2
100
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2026-02-05
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-04
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin
AstraZeneca
Phase 3
2,130
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-02-03
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
NCT06696755Bipolar I Disorder, Bipolar II Disorder
DrugIcalcaprant
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-02-03
Recruiting
Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses
NCT07229352Myopia, Myopia Progression, Juvenile Myopia
SightGlass Vision, Inc.
Not applicable
20
Arizona
2026-02-02
Recruiting
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07213973Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 2
40
Alabama, Arizona, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2026-02-02
Recruiting
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
NCT07322003Amyotrophic Lateral Sclerosis
DrugPridopidine
Prilenia
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland
2026-02-01
Recruiting
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
NCT07428538Hepatitis
Bausch Health Americas, Inc.
Phase 3
350
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-01-29
Recruiting
A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects
NCT07223333Type 2 Diabetes
AdipoPharma LLC
Phase 1
56
Arizona, Florida
2026-01-27
Recruiting
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07259317Adenocarcinoma, Carcinoma, Pancreatic Ductal
DrugsRelacorilant·Nab-paclitaxel·Gemcitabine
Corcept Therapeutics
Phase 2
80
Arizona, California, Florida, Georgia, Indiana, Kansas, Michigan, Minnesota
2026-01-27
Recruiting
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263Hidradenitis Suppurativa
DrugZasocitinib
Takeda
Phase 2
90
Arizona, Arkansas, California, Florida, Massachusetts, Michigan, New Hampshire, New York
2026-01-26
By invitation
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
NCT07286006Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
372
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2026-01-26
Recruiting
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07287917Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
DrugsDifluoromethylornithine·DFMO·Capivasertib·Fulvestrant
Aminex Therapeutics, Inc.
Phase 1/2
92
Arizona, California, Colorado, Kansas, Michigan, Minnesota, New York, Ohio
2026-01-26
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190Uveal Melanoma
DrugDarovasertib
IDEAYA Biosciences
Phase 3
520
Arizona, California, Colorado, Florida, Maryland, Massachusetts, Michigan, Minnesota
2026-01-25
Active, closed
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415Obesity, Overweight
DrugRetatrutide
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Hawaii, Kentucky, Massachusetts, Michigan, New York
2026-01-24
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
DrugsPomalidomide·Dexamethasone
CellCentric Ltd.
Phase 2
100
Arizona, California, Florida, Georgia, Illinois, Iowa, Maryland, Massachusetts
2026-01-22
Recruiting
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring
Phase 2
84
Arizona, California, Florida, Indiana, Louisiana, Maryland, Michigan, Minnesota
2026-01-22
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07185009Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
751
Arizona, California, Colorado, Florida, Indiana, Louisiana, Michigan, Missouri
2026-01-16
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
NCT07321106Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC
Cartography Biosciences
Phase 1
80
Arizona, California, Florida, Georgia, Michigan, Texas, Virginia
2026-01-15
Recruiting
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT07266402Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
240
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Kentucky
2026-01-15
Recruiting
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
NCT07398417Fibromyalgia
DrugEsreboxetine
Axsome Therapeutics, Inc.
Phase 3
620
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas
2026-01-14
Recruiting
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292Multiple Sclerosis
DrugsMRI contrast-enhancing preparations·Frexalimab
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland
2026-01-14
Recruiting
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
NCT07382167Chronic Idiopathic Constipation (CIC)
DrugTenapanor
Ardelyx
Phase 3
692
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-01-13
Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
DrugsRondecabtagene autoleucel·Axi-cel·Breyanzi·Lisocabtagene maraleucel
Lyell Immunopharma, Inc.
Phase 3
400
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-01-12
Active, closed
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
NCT07365826Pneumococcal Vaccines
Drug31-valent pneumococcal conjugate vaccine
Vaxcyte, Inc.
Phase 3
1,390
Arizona, Colorado, Florida, Indiana, Kansas, Kentucky, Michigan, Nebraska
2026-01-12
Recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901Obesity With Diabetes, Overweight With Diabetes
DrugRibupatide
Kailera
Phase 3
1,156
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2026-01-12
Recruiting
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
NCT07643896Pregnant Individuals, Aneuploidy, Down Syndrome (Trisomy 21), 22q11.2 Deletion Syndrome
BillionToOne Inc.
Observational
1,000
Arizona, California, Florida, Georgia, Louisiana, Texas
2026-01-10
Recruiting
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
NCT07358078Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Observational
2,000
Arizona, California, Florida, Kansas, Massachusetts, Missouri, New Jersey, North Carolina
2026-01-09
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1
27
Arizona, California, Illinois, Michigan, Missouri, New York, North Carolina, Washington
2026-01-09
Recruiting
A Study of Buntanetap in Participants With PD
NCT07284784Parkinson's Disease (PD), Deep Brain Stimulation
DrugBuntanetap/posiphen
Annovis Bio Inc.
Phase 2/3
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2026-01-09
Recruiting
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT07095452Multiple Myeloma
DrugsEtentamig·Daratumumab·Lenalidomide·Dexamethasone
AbbVie
Phase 2/3
680
Arizona, California, Colorado, Georgia, Indiana, Minnesota, New York, North Carolina
2026-01-08
Recruiting
Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening
NCT07219277Breast Cancer, Liquid Biopsy, Early Detection
Syantra Inc.
Observational
2,000
Arizona, New York
2026-01-07
Recruiting
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380Pulmonary Hypertension, Interstitial Lung Disease
DrugTreprostinil Palmitil
Insmed Incorporated
Phase 3
344
Arizona, California, Florida, Kansas, New York, North Carolina, Ohio, Oregon
2026-01-07
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Arizona, Arkansas, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-01-06
Recruiting
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT07115329Major Depressive Disorder
DrugZelquistinel
Syndeio Biosciences, Inc
Phase 2
164
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-01-05
Recruiting
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
NCT07384975Hidradenitis Suppurativa (HS)
Navigator Medicines, Inc.
Phase 2
150
Arizona, Florida, Kentucky, Massachusetts, Mississippi, New Hampshire, New York
2026-01-05
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel
Bristol-Myers Squibb
Phase 2/3
590
Alaska, Arizona, Arkansas, California, Delaware, Florida, Idaho, Illinois
2026-01-02
Recruiting
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
NCT06615635Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised, Carcinoma, Squamous
Alpha Tau Medical LTD.
Not applicable
28
Arizona, Florida, Georgia, Minnesota, New York
2026-01-01
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
DrugsFolfiri·Pumitamig·Folfox·Bevacizumab
Bristol-Myers Squibb
Phase 2/3
990
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa
2025-12-31
Recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT07284979Obesity
DrugsRibupatide·Wegovy·Semaglutide
Kailera
Phase 3
1,200
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas
2025-12-30
Recruiting
Renal Pelvic Denervation Pilot Trial
NCT07005050Uncontrolled Hypertension
Verve Medical, Inc
Not applicable
60
Alabama, Arizona, Minnesota, Nevada
2025-12-30
Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
Cogent Biosciences, Inc.
Phase 1
100
Arizona, Connecticut, Florida, Illinois, Louisiana, Michigan, Minnesota, Missouri
2025-12-30
Active, closed
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
NCT07109414Platinum-resistant Ovarian Cancer
DrugPrilukae
Novita Pharmaceuticals, Inc.
Phase 2/3
380
Arizona, Louisiana, New Mexico, Pennsylvania, Utah, Wisconsin
2025-12-29
Active, closed
A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)
NCT07300280Healthy
DrugsEnlicitide·Rosuvastatin
Merck Sharp & Dohme LLC
Phase 1
60
Arizona
2025-12-29
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569Hidradenitis Suppurativa
Sanofi
Phase 2
144
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky
2025-12-29
Recruiting
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
NCT07104565Immune Thrombocytopenia
Incyte Corporation
Phase 2
56
Arizona, California, Colorado, Connecticut, Florida, Massachusetts, New York, Virginia
2025-12-29
Recruiting
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
NCT07110454Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Observational
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Minnesota
2025-12-23
Recruiting
Diagnosing Epilepsy To EffeCT Change
NCT07110337Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Not applicable
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Michigan
2025-12-23
Recruiting
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
NCT07254806Degenerative Disc Disease
DiscGenics, Inc.
Phase 3
162
Alabama, Arizona, California, District of Columbia, Florida, Idaho, Indiana, Kentucky
2025-12-23
Recruiting
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
NCT07280156Gout
DrugMethotrexate
Protalix
Phase 2
150
Arizona, Arkansas, California, Florida, Georgia, Michigan, Pennsylvania, Texas
2025-12-22
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
DrugsTersolisib·Exemestane·Anastrozole·Abemaciclib
Eli Lilly and Company
Phase 3
800
Alaska, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-12-22
Active, closed
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850Obesity and Overweight
DrugBerobenatide
Pfizer
Phase 3
3,578
Arizona, California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska
2025-12-19
Recruiting
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
NCT07287397Amyotrophic Lateral Sclerosis
Vector Y Therapeutics
Phase 1/2
12
Arizona, California, Florida, Massachusetts, New York, Pennsylvania
2025-12-19
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
DrugsPasritamig·Prednisone/Prednisolone·Docetaxel
Janssen Research & Development, LLC
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-12-19
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
NCT07276997Major Depressive Disorder
DrugIcalcaprant
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Nevada
2025-12-18
Recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875Obesity, Overweight
DrugRibupatide
Kailera
Phase 3
2,340
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-12-18
Recruiting
Study of DONQ52 in Active Celiac Disease
NCT07239336Celiac Disease
Chugai Pharmaceutical
Phase 2
92
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2025-12-16
Recruiting
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07288138Metabolic Dysfunction-associated Steatohepatitis
DrugECC4703
Eccogene
Phase 2
160
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Maryland
2025-12-15
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
1,035
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-12-15
Recruiting
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581Rheumatoid Arthritis
AstraZeneca
Phase 2
320
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-15
Recruiting
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639Hemoglobinopathy, Sickle Cell Disease
Beam Therapeutics Inc.
Observational
50
Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2025-12-15
Recruiting
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
NCT07062588Osteogenesis Imperfecta (OI)
DrugAGA2115
Angitia Incorporated Limited
Phase 2
80
Arizona, Connecticut, Delaware, Indiana, Missouri, New Mexico, Ohio, Oregon
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Idaho
2025-12-12
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
DrugsPF-08634404·Avastin·Bevacizumab
Pfizer
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-12-11
Active, closed
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
DrugsEzetimibe FDC·Obicetrapib
NewAmsterdam Pharma
Phase 3
300
Arizona, California, Florida, Idaho, Illinois, Kentucky, Maine, Maryland
2025-12-11
Recruiting
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
NCT07195591Glioblastoma
DrugTemozolomide
GT Medical Technologies, Inc.
Phase 3
766
Arizona, California, Florida, Georgia, Maryland, New Hampshire, New Jersey, New York
2025-12-10
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559Breast Cancer, Metastatic
DrugsEvorpacept·Eribulin·Herceptin·Vinorelbine
ALX Oncology Inc.
Phase 2
120
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Michigan, Minnesota
2025-12-10
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky
2025-12-10
Active, closed
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839COVID-19, SARS-COV-2 Infection
DrugBNT162b2 Vaccine
BioNTech SE
Phase 3
5,240
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-12-10
Recruiting
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
NCT07290036Psoriatic Arthritis, Axial Spondyloarthritis
UCB Biopharma SRL
Phase 1
392
Arizona, California, Colorado, Florida, Illinois, Michigan, New Jersey, New Mexico
2025-12-10
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2025-12-10
Recruiting
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
NCT07282665Clostridoides Difficile Associated Disease
Pfizer
Phase 3
32,500
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2025-12-10
Recruiting
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373Multiple Sclerosis
AstraZeneca
Phase 1
24
Arizona, Colorado, District of Columbia, Missouri, New York, Ohio, Washington, Wisconsin
2025-12-09
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 3
466
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2025-12-09
Recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210Severe Hypertriglyceridemia
Eli Lilly and Company
Phase 2
60
Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland
2025-12-08
Active, closed
Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain
NCT07700433Back Pain
BTL Industries Ltd.
Not applicable
60
Arizona, Florida, Ohio, Texas
2025-12-08
By invitation
Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic
NCT07417774Glioblastoma (GBM)
NuvOx LLC
Observational
40
Arizona, Connecticut, Missouri, North Carolina
2025-12-08
Recruiting
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
NCT07137598Rheumatoid Arthritis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
160
Arizona, California, Florida, Illinois, Louisiana, Michigan, New York, Ohio
2025-12-05
Active, closed
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
NCT07222917Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 2
222
Arizona, Florida, Georgia, Illinois, Kansas, North Carolina, Ohio, Pennsylvania
2025-12-05
Recruiting
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
NCT06980948Chronic Neuropathic Pain
Sangamo Therapeutics
Phase 1/2
27
Arizona, Arkansas, California, Maryland, Massachusetts, New Hampshire, New York, North Carolina
2025-12-04
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-12-04
Active, closed
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
NCT07310901Obese But Otherwise Healthy Participants
Corbus Pharmaceuticals Inc.
Phase 1
252
Alabama, Arizona, California, Florida, Kentucky, Nevada, New York, North Carolina
2025-12-04
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland
2025-12-03
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana
2025-12-03
Active, closed
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07290569Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
160
Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, New York
2025-12-03
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
DrugsIDRX-42·Sunitinib
GlaxoSmithKline
Phase 3
450
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa
2025-12-03
Recruiting
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
NCT07165132GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
RayzeBio, Inc.
Phase 1
104
Arizona, Florida, Iowa, Kentucky, Minnesota, Missouri, Ohio, Oregon
2025-12-03
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Arizona, California, Florida, Georgia, Maryland, Massachusetts, Michigan, Minnesota
2025-12-02
Recruiting
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
NCT07258849Rheumatoid Arthritis (RA)
Eli Lilly and Company
Phase 1
141
Alabama, Arizona, Florida, Nevada
2025-12-02
Active, closed
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
NCT07284654Pneumococcal Vaccines
Drugs31-valent pneumococcal conjugate vaccine·Capvaxive·Prevnar 20
Vaxcyte, Inc.
Phase 3
4,049
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2025-12-01
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
NCT07284186Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Plexium, Inc.
Phase 1
155
Arizona, California, Massachusetts, Missouri, New York, North Carolina, Ohio, Texas
2025-12-01
Recruiting
Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing
NCT07326553Diabete Mellitus, Foot Ulcer Chronic
BioXTek
Phase 4
30
Arizona, Texas
2025-12-01
Recruiting
Post-market Safety and Effectiveness of the CORUS-LX System in Improving Lumbar Interbody Fusion Outcomes
NCT07222787Radiculopathy Lumbar, Degenerative Lumbar Disc Disease
Providence Medical Technology, Inc.
Not applicable
250
Arizona, California, Illinois, New York, North Carolina, Ohio, Texas, Utah
2025-12-01
Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
NCT07144852Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 3
260
Arizona, California, Colorado, Florida, Idaho, Illinois, Indiana, Minnesota
2025-11-29
Recruiting
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484Type 2 Diabetes, Cortisol Excess
DrugClofutriben
Sparrow Pharmaceuticals
Phase 2
1,500
Arizona, California, Florida, Georgia, Idaho, Illinois, Iowa, Kansas
2025-11-29
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
DrugRina-S
Genmab
Phase 3
660
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-11-28
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel
Amgen
Phase 3
750
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-28
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Alabama, Arizona, California, Florida, Indiana, Michigan, Minnesota, Nebraska
2025-11-27
Recruiting
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc.
Phase 1/2
150
Arizona, California, Colorado, Connecticut, Georgia, Kentucky, Louisiana, Michigan
2025-11-26
Active, closed
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
NCT07266558SARS-CoV-2
DrugsMRNA-1283·Efluelda (TIV-HD) and Spikevax
ModernaTX, Inc.
Phase 4
30,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-26
By invitation
Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
NCT07450664Prader-Willi Syndrome
Soleno Therapeutics, Inc.
Observational
200
Arizona, California, Colorado, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-11-26
Recruiting
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
NCT07233239Focal Seizures
DrugCannabidiol
Jazz Pharmaceuticals
Phase 1
100
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Michigan
2025-11-26
Recruiting
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
NCT07142291Amyotrophic Lateral Sclerosis (ALS)
DrugsCromolyn Sodium·Riluzole
PhenoNet, Inc.
Phase 2
105
Arizona, California, Florida, New York
2025-11-25
By invitation
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
1,370
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-11-25
Recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958Acute Myeloid Leukemias
DrugRevumenib
Syndax Pharmaceuticals
Phase 3
468
Arizona, California, Indiana, Louisiana, Rhode Island, Texas
2025-11-25
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Arizona, California, Florida, Maryland, Michigan, Minnesota, Ohio, Rhode Island
2025-11-24
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-24
Recruiting
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
NCT07209462Fragile X Syndrome
DrugMRM-3379
Mirum Pharmaceuticals, Inc.
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-11-22
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419Diabetic Peripheral Neuropathic Pain
DrugSuzetrigine
Vertex Pharmaceuticals Incorporated
Phase 3
734
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-11-21
Active, closed
Efficacy and Safety of NVX-CoV2705
NCT07086222COVID-19, Sars-CoV-2 Infection
Novavax
Phase 4
6,500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-11-20
Recruiting
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
NCT07216027Atopic Dermatitis, Eczema, Atopic
Pfizer
Phase 2
165
Arizona, California, Florida, New York, Ohio, Pennsylvania
2025-11-20
Recruiting
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
NCT07136181Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma
Novelwise Pharmaceutical Corporation
Phase 1/2
36
Arizona, Colorado, Tennessee
2025-11-20
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
Arizona, California, Connecticut, Florida, Georgia, Iowa, Kentucky, Louisiana
2025-11-19
Recruiting
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448Colorectal Cancer
DrugsONO-4578·Leucovorin·Opdivo·Adrucil
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Arizona, California, Colorado, Florida, Minnesota, Ohio, Pennsylvania, Texas
2025-11-18
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin
Summit Therapeutics
Phase 3
600
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-18
Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT07290803Atopic Dermatitis
Sanofi
Observational
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan
2025-11-17
Active, closed
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT07228390Hidradenitis Suppurativa
DrugRitlecitinib
Pfizer
Phase 2
128
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-11-13
By invitation
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
NCT07223138Arthritis, Psoriatic
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
1,560
Arizona, Arkansas, California, Florida, North Carolina, Ohio, Pennsylvania, Tennessee
2025-11-13
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
NCT07085104Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
DrugsFludarabine·Cyclophosphamide
Allogene Therapeutics
Phase 1
66
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky
2025-11-13
Active, closed
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,060
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-11-12
Active, closed
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
NCT07216482Hyperlipidemia
DrugsEnlicitide·Rosuvastatin
Merck Sharp & Dohme LLC
Phase 3
996
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2025-11-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-11-11
Recruiting
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
NCT07112378Eosinophilic Esophagitis (EoE)
DrugDupilumab
Regeneron Pharmaceuticals
Phase 3
20
Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2025-11-10
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Arizona, California, Florida, Maryland, Nevada, Pennsylvania, Texas, Utah
2025-11-10
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Massachusetts
2025-11-10
Recruiting
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
NCT07220876Open Angle Glaucoma (OAG)
Avisi Technologies Inc.
Not applicable
165
Arizona, California, Colorado, Ohio, Pennsylvania, Texas, Wisconsin
2025-11-07
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917Hidradenitis Suppurativa
DrugBrivekimig
Sanofi
Phase 2
208
Arizona, California, Florida, Georgia, Iowa, Louisiana, Missouri, Nevada
2025-11-06
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Neovascular Age-related Macular Degeneration
DrugSurabgene Lomparvovec
AbbVie
Phase 3
561
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2025-11-05
Active, closed
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759Overweight, Obesity, Type 2 Diabetes
DrugCagrilintide
Novo Nordisk A/S
Phase 3
330
Alabama, Arizona, California, Florida, Hawaii, Indiana, Nevada, New York
2025-11-05
Recruiting
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 1
24
Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-11-03
Active, closed
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT07287644Hidradenitis Suppurativa (HS)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2/3
210
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Michigan
2025-11-03
Active, closed
At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]
NCT07163221Rheumatoid Arthritis (RA)
DrugConventional Synthetic DMARD
SecondWave Systems Inc.
Not applicable
60
Arizona, California, Colorado, Minnesota
2025-11-03
Recruiting
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
NCT07098858Heart Failure
EBR Systems, Inc.
Observational
320
Arizona, Arkansas, Florida, Michigan, Missouri, New York, Ohio, Pennsylvania
2025-11-03
Recruiting
CCM OPEN HF Registry
NCT07112924Heart Failure
Impulse Dynamics
Observational
5,500
Arizona, Florida, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New Hampshire
2025-11-01
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2025-10-31
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
DrugsDato-DXd·Docetaxel
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois
2025-10-31
Recruiting
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
NCT07142356Uncontrolled Hypertension
Retension Pharmaceuticals. Inc.
Phase 2
280
Alabama, Arizona, California, Connecticut, Florida, Georgia, Indiana, Louisiana
2025-10-31
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051Bronchiectasis
DrugGSK3862995B
GlaxoSmithKline
Phase 2
363
Alabama, Arizona, California, Colorado, Florida, Indiana, Louisiana, Maryland
2025-10-30
Recruiting
EDX110 Randomized Control Trial for Treatment of DFUs
NCT07209358Wound Heal, Diabetic Foot Ulcer
ConvaTec Inc.
Not applicable
298
Arizona, California, Texas
2025-10-30
Recruiting
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
NCT07332000Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
DrugsAglatimagene besadenovec·Valacyclovir
Candel Therapeutics, Inc.
Phase 2
45
Arizona, Colorado, Maryland, Nevada, New Jersey, South Carolina
2025-10-30
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615Chronic Spontaneous Urticaria
DrugsLitfulo·Ritlecitinib
Pfizer
Phase 2
200
Arizona, Arkansas, California, Colorado, Illinois, Maryland, Michigan, Oklahoma
2025-10-30
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-10-28
Recruiting
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT06405087Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-10-27
By invitation
Assessment of Non-Invasive Testing in Major Liver-Related Outcomes
NCT06986447Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
HRI-MAIL-NIT
Observational
1,689
Arizona, Ohio, Texas
2025-10-25
Recruiting
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
NCT07221227Non-alcoholic Fatty Liver Disease
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
1,200
Arizona, Arkansas, California, Colorado, Florida, Georgia, Kansas, Louisiana
2025-10-24
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-24
Recruiting
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
NCT07207369Acne Scars
AbbVie
Phase 3
395
Arizona, California, Connecticut, Georgia, Maryland, New York, North Carolina, Texas
2025-10-24
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Kansas
2025-10-23
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Arizona, California, Colorado, Florida, Illinois, Kentucky, Massachusetts, Nevada
2025-10-22
Recruiting
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
NCT07069738Heart Failure - NYHA II - IV
Boston Scientific Corporation
Not applicable
850
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2025-10-22
Recruiting
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
NCT07403669Acute MI, Heart Failure, Diabetes Mellitus, Kidney Disease
Aventyn, Inc.
Not applicable
300
Arizona
2025-10-22
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan
Eli Lilly and Company
Phase 3
1,630
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-10-22
Recruiting
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
NCT07220811Ig-E Mediated Food Allergy
DrugOzureprubart
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Phase 2
100
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Massachusetts
2025-10-22
Recruiting
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System
NCT07227532Atrial Fibrillation
Biosense Webster, Inc.
Not applicable
276
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Michigan
2025-10-21
Active, closed
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
NCT07074977Chronic Pruritus of Unknown Origin
DrugNemolizumab
Galderma R&D
Phase 2
50
Alabama, Arizona, California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-10-20
Recruiting
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
NCT07215559Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsMacupatide·Eloralintide
Eli Lilly and Company
Phase 2
200
Arizona, Florida, Georgia, Nevada, New Jersey, Ohio, Texas, Utah
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Arizona, Arkansas, California, Florida, Illinois, Maryland, Massachusetts, New York
2025-10-16
Recruiting
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NCT06800963NMIBC
ImmunityBio, Inc.
Phase 1/2
40
Arizona, California, Georgia, Michigan, New York, Pennsylvania, Tennessee, Virginia
2025-10-15
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Maryland
2025-10-15
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-10-15
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
DrugBexobrutideg
Nurix Therapeutics, Inc.
Phase 2
100
Arizona, California, Colorado, Florida, Indiana, Iowa, Maryland, Michigan
2025-10-15
Recruiting
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
NCT07187479Chronic Kidney Disease (Stages 4 and 5), Kidney Disease, Type 2 Diabetes
Well Cell Global
Not applicable
120
Arizona
2025-10-14
Active, closed
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
NCT07215312Diabetes Mellitus, Type 2
DrugsLY3938577·Degludec
Eli Lilly and Company
Phase 2
100
Arizona, California, Florida, Iowa, Missouri, North Carolina, Oklahoma, South Carolina
2025-10-13
Recruiting
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234Geographic Atrophy
Sanofi
Phase 1/2
104
Arizona, California, Florida, Georgia, Illinois, Maryland, Nevada, North Carolina
2025-10-09
Recruiting
Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease
NCT07207122Parkinson Disease
Sanmai Technologies PBC dba Sanmai
Not applicable
60
Arizona, California, Florida, New York
2025-10-08
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
DrugsTulisokibart·Methotrexate
Merck Sharp & Dohme LLC
Phase 2
185
Arizona, California, Colorado, Florida, Illinois, Michigan, Missouri, Nebraska
2025-10-08
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07184996Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-08
Recruiting
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT07100106Breast Cancer
DrugsRGT-419B·Giredestrant·Abemaciclib
Genentech, Inc.
Phase 1/2
285
Arizona, California, Florida, Georgia, Illinois, Maine, Maryland, Massachusetts
2025-10-07
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
DrugPonsegromab
Pfizer
Phase 2/3
982
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Hawaii
2025-10-03
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-03
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
DrugNNC6019-0001
Novo Nordisk A/S
Phase 3
1,280
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois
2025-10-02
Active, closed
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity
NCT07184632Overweight, Obesity
DrugNNC0662-0419
Novo Nordisk A/S
Phase 2
224
Arizona, Nebraska
2025-10-01
Recruiting
Evaluation of the Medentum Diagnostik Platform for Pediatric ENT Conditions and Asthma
NCT07500532Acute Otitis Media (AOM), Strep Pharyngitis, Asthma Exacerbation, Pediatric Asthma
Medentum Innovations
Not applicable
84
Arizona
2025-10-01
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-01
Recruiting
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
NCT07008118Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
120
Arizona, California, Colorado, Florida, Illinois, Maryland, New York, North Carolina
2025-10-01
By invitation
A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
NCT07204938Hereditary Angioedema (HAE)
DrugNavenibart
Astria Therapeutics, Inc.
Phase 3
145
Arizona, Arkansas, California, Colorado, Maryland, Ohio, Pennsylvania
2025-10-01
Recruiting
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
NCT07175038Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
AllRock Bio, Inc.
Phase 2
40
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Michigan, Ohio
2025-10-01
Recruiting
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
NCT06910306Recurrent Glioblastoma, Recurrent Gliomas
Alpha Tau Medical LTD.
Not applicable
10
Arizona, New York, Ohio
2025-10-01
Recruiting
Study of COYA 302 for the Treatment of ALS
NCT07161999Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics
Phase 2/3
120
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-10-01
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-01
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
470
Arizona, California, Colorado, District of Columbia, Florida, Kentucky, Maryland, Massachusetts
2025-09-30
Recruiting
IVUS CHIP UPP Registry
NCT06625801Coronary Artery Disease, Coronary Artery Disease Risk High, Complex Coronary Artery Disease
ECRI bv
Observational
1,010
Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan, Minnesota
2025-09-30
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, Pennsylvania
2025-09-30
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
DrugsPovetacicept·Tacrolimus
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-09-30
Active, closed
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
NCT07220460Bipolar I or II Disorder
DrugABBV-932
AbbVie
Phase 2
84
Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland
2025-09-30
Recruiting
RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial
NCT06813820Left Ventricle Remodeling, Left Ventricle Dilated, CHF
BioVentrix
Not applicable
135
Arizona, Florida, Illinois, Missouri, Oklahoma, Pennsylvania
2025-09-29
Recruiting
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
NCT07161544Stargardt Disease
AAVantgarde Bio Srl
Phase 1/2
75
Arizona, California, Florida, Minnesota, Texas, Utah
2025-09-29
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsMevrometostat·Xtandi·Enzalutamide
Pfizer
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-09-28
Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312Acute Myeloid Leukemia (AML)
DrugsZiftomenib·Venclyxto·Ara-C·Daunorubicin
Kura Oncology, Inc.
Phase 3
1,300
Arizona, California, Colorado, Connecticut, Florida, Iowa, Kentucky, Massachusetts
2025-09-26
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
315
Arizona, California, Florida, Illinois, Maryland, Missouri, Montana, Nebraska
2025-09-26
Active, closed
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
NCT07159763Influenza
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-09-25
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
DrugsUstekinumab·Deucravacitinib
Bristol-Myers Squibb
Phase 3
3,040
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-09-22
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
DrugZilebesiran
Alnylam Pharmaceuticals
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-09-22
Active, closed
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
NCT07221578Social Anxiety Disorder (SAD)
Vanda Pharmaceuticals
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri
2025-09-22
Recruiting
DESTINY-PANTUMOUR04
NCT07124000Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Observational
100
Alabama, Arizona, California, Colorado, Florida, Illinois, Kansas, New Mexico
2025-09-18
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222Chronic Obstructive Pulmonary Disease
DrugLunsekimig
Sanofi
Phase 3
942
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-09-17
Active, closed
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,101
Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Louisiana
2025-09-17
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
DrugsAZD0754·AZD5851
AstraZeneca
Observational
64
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, Missouri
2025-09-17
Recruiting
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
NCT07037758Extensive Stage Small Cell Lung Cancer
DrugsEtakafusp alfa·Tarlatamab
Amgen
Phase 1
380
Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Missouri, New York
2025-09-16
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
DrugLunsekimig
Sanofi
Phase 3
942
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana
2025-09-16
Recruiting
Phagenyx® Registry Study
NCT06866418Dysphagia
Phagenesis Ltd.
Observational
600
Arizona, New Jersey, Texas
2025-09-15
Recruiting
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
NCT07090161Hypertension, Uncontrolled Hypertension
DrugIloperidone
Vanda Pharmaceuticals
Phase 2
240
Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky, Missouri
2025-09-15
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
DrugsApitegromab·Nusinersen·Risdiplam
Scholar Rock, Inc.
Phase 2
52
Arizona, California, Colorado, Georgia, Iowa, Michigan, Pennsylvania, Texas
2025-09-15
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Kansas, Massachusetts
2025-09-15
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
413
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-09-13
Active, closed
A Study in Subjects With Neurogenic Orthostatic Hypotension
NCT07089043Neurogenic Orthostatic Hypotension
CuraSen Therapeutics, Inc.
Phase 2
12
Arizona, Michigan, New Jersey, New York, Tennessee
2025-09-12
Recruiting
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
NCT07205887Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
DrugsRestoret·Aflibercept
EyeBiotech Ltd.
Phase 2
160
Arizona, California, Colorado, Florida, Illinois, Maryland, Mississippi, New Jersey
2025-09-12
Recruiting
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
NCT07020819Guillain-Barre Syndrome
Annexon, Inc.
Phase 3
30
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-09-12
Recruiting
AMEND TS Early Feasibility Study
NCT06951672Symptomatic Functional MR 3 or Greater
Valcare Medical Ltd.
Not applicable
15
Arizona, California, Georgia, Indiana, New York, Oregon, Tennessee, Texas
2025-09-11
Rows per page Showing 1–500 of 2238
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/arizona

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,238 of those studies with a site in Arizona.

How many clinical trials are recruiting in Arizona?

1,129 of the 2,238 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 31 have not yet opened recruitment, 1,021 are active but closed to new participants, and 57 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Arizona), 2,238 studies
PhaseStudiesRecruitingShare
Phase 391142340.7%
Phase 243621319.5%
Not applicable24411010.9%
Observational1831068.2%
Phase 11811138.1%
Phase 1/21651017.4%
Phase 2/375403.4%
Phase 442221.9%
Phase EARLY_PHASE1110%

Most active sponsors

Lead sponsors with the most studies (Arizona)
Lead sponsorStudiesRecruiting
AstraZeneca11464
Eli Lilly and Company9652
AbbVie7427
Merck Sharp & Dohme LLC6225
Janssen Research & Development, LLC4920
Novartis Pharmaceuticals4821
Pfizer4628
Sanofi4321
Bristol-Myers Squibb3719
Hoffmann-La Roche3612
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.